Table 3. Susceptibility of species among 11,943 bacteria isolated from urine cultures collected between 2005-2006, and 2010-2011 at the University Hospital of the University of São Paulo (HU-USP).
| Antibiotic | Escherichia coli | Proteus mirabilis | Klebsiella pneumoniae | Enterococcus faecalis | Enterobacter aerogenes | S. saprophyticus | Pseudomonas aeruginosa | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2005-2006 | 2010-2011 | p | 2005-2006 | 2010-2011 | p | 2005-2006 | 2010-2011 | p | 2005-2006 | 2010-2011 | p | 2005-2006 | 2010-2011 | p | 2005-2006 | 2010-2011 | P | 2005–2006 | 2010–2011 | P | |
| Nalidixic acid | 90.1% | 78.1% | <0.0001 | 91.6% | 85.9% | 0.011 | 87.1% | 74.9% | <0.0001 | 86.2% | 90% | 0.422 | 42.9% | ||||||||
| Amikacin | 99.8% | 99.8% | 0.783 | 98.8% | 99.7% | 0.316 | 96.7% | 99.7% | 0.006 | 95.3% | 96.9% | 0.932 | 78.6% | 95.5% | 0.004 | ||||||
| Amoxicillin/clavulanate | 83.5% | 86.8% | <0.0001 | 91.9% | 78.6% | <0.0001 | 90.4% | 84.9% | 0.034 | 5.7% | 1% | 0.155 | 28.6% | ||||||||
| Ampicillin | 100% | 90.2% | 0.004 | ||||||||||||||||||
| Cefazolin | 95.2% | 91.9% | 0.040 | 95.6% | 76.2% | 0.023 | 95.3% | 79.2% | 0.054 | 17.4% | 0% | 0.888 | |||||||||
| Cefepime | 99.6% | 97.2% | <0.0001 | 98.2% | 95.4% | 0.035 | 94.8% | 84.2% | <0.0001 | 95.3% | 97.9% | 0.643 | 80.3% | 92.4% | 0.076 | ||||||
| Ceftazidime | 100% | 95.4% | 1.000 | 50% | 85.5% | 0.073 | 95% | 75.8% | 92.4% | 0.017 | |||||||||||
| Ceftriaxone | 99.6% | 97.8% | <0.0001 | 98.5% | 81% | <0.0001 | 95.9% | 91.7% | 0.328 | 93% | 100% | 1.000 | |||||||||
| Cefuroxime axetil | 96.8% | 92.3% | <0.0001 | 96.9% | 81% | 0.003 | 88.6% | 87.5% | 1.000 | ||||||||||||
| Ciprofloxacin | 92.9% | 84.9% | <0.0001 | 95.1% | 87.9% | <0.0001 | 89.9% | 78.1% | <0.0001 | 73.9% | 74.8% | 0.859 | 92% | 92% | 0.991 | 100% | 100% | 1.000 | 68.2% | 89.4% | 0.003 |
| Clindamycin | 99.3% | ||||||||||||||||||||
| Colistin | 100% | 0% | 66.7% | ||||||||||||||||||
| Erythromycin | 79.5% | ||||||||||||||||||||
| Ertapenem | 100% | 99.5% | 98.5% | 100% | |||||||||||||||||
| Streptomycin | 68.8% | ||||||||||||||||||||
| Streptomycin (high level resistance) | 78.8% | ||||||||||||||||||||
| Gentamicin | 96.6% | 94.3% | <0.0001 | 95.8% | 91.5% | 0.013 | 94.9% | 90.1% | 0.021 | 100% | 96.6% | 97% | 1.000 | 61.5% | 89.4% | <0.0001 | |||||
| Gentamicin (high level resistance) | 78.8% | 79.8% | 0.206 | ||||||||||||||||||
| Imipenem | 100% | 100% | 1.000 | 100% | 100% | 1.000 | 100% | 100% | 1.000 | 100% | 89.4% | 91.2% | 0.762 | ||||||||
| Levofloxacin | 100% | 100% | |||||||||||||||||||
| Linezolid | 97.5% | 98.9% | 1.000 | ||||||||||||||||||
| Meropenem | 100% | 100% | 1.000 | 100% | 100% | 1.000 | 100% | 100% | 85% | 92.4% | |||||||||||
| Minocycline | |||||||||||||||||||||
| Nitrofurantoin | 98.4% | 92.3% | <0.0001 | 1% | 0% | 0.147 | 63% | 32.7% | <0.0001 | 100% | 97.3% | 0.478 | 47.1% | 5% | <0.0001 | 99.3% | 28.6% | ||||
| Norfloxacin | 92.7% | 85.7% | <0.0001 | 94.8% | 100% | 0.695 | 89.7% | 82.6% | 0.479 | 92% | 100% | 1.000 | 67.9% | 86.7% | 0.037 | ||||||
| Oxacillin | 100% | ||||||||||||||||||||
| Penicillin G | 89.8% | 85.9% | 0.294 | ||||||||||||||||||
| Piperacillin/tazobactam | 100% | 96.9% | 1.000 | 100% | 96.2% | 1.000 | 16.7% | 88.7% | <0.0001 | 87.5% | 89.4% | 94% | 0.588 | ||||||||
| Rifampin | 99.3% | 100% | 1.000 | ||||||||||||||||||
| Tetracycline | 26.8% | 18.9% | 0.326 | 81.5% | |||||||||||||||||
| Trimethoprim/sulfamethoxazole | 65% | 62.9% | 0.023 | 77.8% | 74.5% | 0.268 | 82.7% | 77.9% | <0.0001 | 92% | 94% | 0.583 | 95.2% | 3.1% | |||||||
| Vancomycin | 98.6% | 97.3% | 0.699 | 100% | 100% | 1.000 | |||||||||||||||
Note:
*
p < 0.05 compared between gender within each stratum of age indicated (Pearson uncorrected chi-square test or Fisher's exact test when values ≤ 5).